Literature DB >> 32771306

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians.

V Subbiah1, D B Solit2, T A Chan3, R Kurzrock4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32771306     DOI: 10.1016/j.annonc.2020.07.002

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  48 in total

1.  High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.

Authors:  D J McGrail; P G Pilié; N U Rashid; L Voorwerk; M Slagter; M Kok; E Jonasch; M Khasraw; A B Heimberger; B Lim; N T Ueno; J K Litton; R Ferrarotto; J T Chang; S L Moulder; S-Y Lin
Journal:  Ann Oncol       Date:  2021-03-15       Impact factor: 32.976

Review 2.  Targeting the DNA damage response in immuno-oncology: developments and opportunities.

Authors:  Roman M Chabanon; Mathieu Rouanne; Christopher J Lord; Jean-Charles Soria; Philippe Pasero; Sophie Postel-Vinay
Journal:  Nat Rev Cancer       Date:  2021-08-10       Impact factor: 60.716

3.  Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology.

Authors:  Renzo G DiNatale; A Ari Hakimi; Timothy A Chan
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

Review 4.  Loose Regulatory Standards Portend a New Era of Imprecision Oncology.

Authors:  Ali Raza Khaki
Journal:  Cancer Invest       Date:  2021-01-07       Impact factor: 2.176

Review 5.  The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors.

Authors:  Arjun Mittra; Naoko Takebe; Vaia Florou; Alice P Chen; Abdul Rafeh Naqash
Journal:  Hum Vaccin Immunother       Date:  2020-12-16       Impact factor: 3.452

Review 6.  Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview.

Authors:  Jesús García-Foncillas; Jesús Argente; Luis Bujanda; Victoria Cardona; Bonaventura Casanova; Ana Fernández-Montes; José A Horcajadas; Andrés Iñiguez; Alberto Ortiz; José L Pablos; María Vanessa Pérez Gómez
Journal:  Mol Diagn Ther       Date:  2021-07-30       Impact factor: 4.074

7.  ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.

Authors:  Bruna Pellini; Nadja Pejovic; Wenjia Feng; Noah Earland; Peter K Harris; Abul Usmani; Jeffrey J Szymanski; Faridi Qaium; Jacqueline Mudd; Marvin Petty; Yuqiu Jiang; Ashla Singh; Christopher A Maher; Lauren E Henke; Haeseong Park; Matthew A Ciorba; Hyun Kim; Matthew G Mutch; Katrina S Pedersen; Benjamin R Tan; William G Hawkins; Ryan C Fields; Aadel A Chaudhuri
Journal:  JCO Precis Oncol       Date:  2021-02-12

Review 8.  The treatment landscape of metastatic prostate cancer.

Authors:  Yasutaka Yamada; Himisha Beltran
Journal:  Cancer Lett       Date:  2021-06-18       Impact factor: 8.679

9.  Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma.

Authors:  Kyrollis Attalla; Renzo G DiNatale; Phillip M Rappold; Christopher J Fong; Francisco Sanchez-Vega; Andrew W Silagy; Stanley Weng; Jonathan Coleman; Chung-Han Lee; Maria I Carlo; Jeremy C Durack; Stephen B Solomon; Victor E Reuter; Paul Russo; Timothy A Chan; Robert J Motzer; Nikolaus D Schultz; Ed Reznik; Martin H Voss; A Ari Hakimi
Journal:  Clin Cancer Res       Date:  2021-07-14       Impact factor: 12.531

10.  Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.

Authors:  Arnaud Da Cruz Paula; Deborah F DeLair; Lorenzo Ferrando; Daniel J Fix; Robert A Soslow; Kay J Park; Sarah Chiang; Jorge S Reis-Filho; Ahmet Zehir; Mark T A Donoghue; Michelle Wu; David N Brown; Rajmohan Murali; Claire F Friedman; Dmitriy Zamarin; Vicky Makker; Jennifer J Mueller; Mario M Leitao; Nadeem R Abu-Rustum; Carol Aghajanian; Britta Weigelt
Journal:  Gynecol Oncol       Date:  2021-02-21       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.